Tag Archives: BIND Therapeutics

Targeted Nanoparticles for Cancer – optimizing physiochemical properties for enhanced tumor-killing

Last week, BIND Therapeutics and Amgen ended a collaboration on a targeted nanaoparticle that employed a proprietary cytotoxic compound from Amgen.  However, BIND has several other programs (and partnerships with AstraZeneca, Roche, and Pfizer) that are proceeding in the clinic, which employ its Targeted Nanoparticle (TNP) technology.  How does this work? Continue reading